News | January 14, 2009

Doctors Request More Funding for Imaging Prostate Cancer

January 14, 2009 – Leaders from the medical field and academia urge Obama Administration, Congress, the National Institutes of Health and the Department of Defense to increase federal funding for research into imaging technologies for less invasive and more accurate diagnosis of prostate cancer.

“We lack the accurate imaging tools that would help us perform better biopsies and design more optimal treatments for our patients,” said Theodore DeWeese, M.D., chair of Radiation Oncology at Johns Hopkins University, who was among the conference participants to support the consensus statement.

Meeting this week in Bethesda, MD, at a conference convened by the AdMeTech Foundation, the medical experts discussed strategies for speeding development of imaging technologies for prostate cancer modeled after life-saving mammograms for women. They reportedly agreed that advanced prostate imaging would save lives and an estimated $5 billion per year in healthcare costs.

“As physicians, scientists, educators and patients, we are personally concerned about the human and societal costs of prostate cancer. We firmly believe that more accurate imaging technology would lead to better patient care, including guidance for diagnosis, biopsy and minimally invasive therapy,” today’s consensus statement reads. “The AdMeTech Foundation conference clearly demonstrated that real and important improvements in prostate cancer care are at hand if we are resolved to increase the national investment in prostate diagnostics.”

Conference participants also signed a letter to Dr. Raynard S. Kington, acting director of the National Institutes of Health, urging increased federal research funding for prostate cancer imaging diagnostics.

The clinical experts met over the past two days as a result of the meeting between leadership of the AdMeTech Foundation, advocacy groups, and industry with Dr. Elias Zerhouni, director of NIH, in the spring of 2008. The experts unanimously agreed that prostate cancer care is in a state of crisis due to the lack of reliable imaging tools critical to guiding early detection, accurate diagnosis and the most effective and least invasive treatment.

For more information: www.admetech.org

Related Content

SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Overlay Init